These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 18181718

  • 21. Specifications from a biotechnology industry perspective.
    Garnick RL.
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [Abstract] [Full Text] [Related]

  • 22. Experience with validation of clinical trial materials: an inspector's viewpoint.
    Wolfe L.
    Dev Biol (Basel); 2003; 113():27-33. PubMed ID: 14620849
    [Abstract] [Full Text] [Related]

  • 23. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ, Mire-Sluis A.
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [Abstract] [Full Text] [Related]

  • 24. Dosage form design and development.
    Allen LV.
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Legal regulations to produce serum eye drops : when is it necessary, and how can it be obtained?].
    Geerling G, Grus F, Seitz B, Hartwig D, Schirra F.
    Ophthalmologe; 2008 Jul; 105(7):632-8. PubMed ID: 18587585
    [Abstract] [Full Text] [Related]

  • 32. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J.
    Ann Ist Super Sanita; 1969 Jul; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Challenges in natural health product research: The importance of standardization.
    Shan JJ, Rodgers K, Lai CT, Sutherland SK.
    Proc West Pharmacol Soc; 2007 Jul; 50():24-30. PubMed ID: 18605225
    [Abstract] [Full Text] [Related]

  • 35. Current marketplace for probiotics: a Japanese perspective.
    Amagase H.
    Clin Infect Dis; 2008 Feb 01; 46 Suppl 2():S73-5; discussion S144-51. PubMed ID: 18181727
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
    Mattia A, Merker R.
    Clin Infect Dis; 2008 Feb 01; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
    [Abstract] [Full Text] [Related]

  • 39. Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo-diagnostic use in case of introduction of changes in the manufacturing process.
    Schäffner G, Haase M, Giess S.
    Biologicals; 1995 Sep 01; 23(3):253-9. PubMed ID: 8527127
    [Abstract] [Full Text] [Related]

  • 40. Toward biotherapeutic product real-time quality monitoring.
    Guerra A, von Stosch M, Glassey J.
    Crit Rev Biotechnol; 2019 May 01; 39(3):289-305. PubMed ID: 30724608
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.